Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center-Reference-Cited by-同舟云学术

Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center

Published:2022-04-16 Issue:10 Volume:42 Page:1767-1774
ISSN:1437-160X
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Choi May Y.^ORCID,Weber Brittany,Stevens Emma,Guan Hongshu,Ellrodt Jack,Oakes Emily,Di Carli Marcelo,Tedrow Usha,Sauer William,Costenbader Karen H.^ORCID

Funder

Lupus Foundation of America

National Institutes of Health

American Heart Association

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s00296-022-05125-0.pdf

Reference24 articles.

1. Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, Hua C (2020) Clinical and structural efficacy of hydroxychloroquine in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 72(1):36–40. https://doi.org/10.1002/acr.23826

2. Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Munoz S, Testi A, Plaza J, Sentis J, Coca A (2008) Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 17(4):281–288. https://doi.org/10.1177/0961203307086503

3. Pons-Estel GJ, Alarcon GS, McGwin G, Jr., Danila MI, Zhang J, Bastian HM, Reveille JD, Vila LM, Lumina Study G (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 61(6):830–839. https://doi.org/10.1002/art.24538

4. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69(1):20–28. https://doi.org/10.1136/ard.2008.101766

5. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrom K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736–745. https://doi.org/10.1136/annrheumdis-2019-215089

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Taking hydroxychloroquine to heart;Journal of the American Academy of Dermatology;2024-07

2. Hydroxychloroquine, Chloroquine and arrhythmic risk in systemic autoimmune diseases: focus more on the patient and you will keep the rhythm!;Journal of Cardiovascular Pharmacology;2024-05-20

3. Hydroxychloroquine and Chloroquine-Induced Cardiac Arrhythmias and Sudden Cardiac Death in Patients with Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis;Journal of Cardiovascular Pharmacology;2024-05-08

4. Cardiac manifestations in patients with systemic lupus erythematosus and rheumatoid arthritis: Relation to long-term use of hydroxychloroquine;The Egyptian Rheumatologist;2024-01